Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.